GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Diclofenac potassium (Cambia), oral powder

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Cambia - labeled renal guidance

Product / population
Diclofenac potassium (Cambia), oral powder
Renal method
Renal impairment categories as defined by the cited product label
Source revision
DailyMed SPL version 9, posted Dec 16, 2024
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Cambia - product and source limitations

If treatment is necessary, monitor renal function. Verify the formulation used for migraine.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Cambia - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Diclofenac potassium (Cambia), oral powder

Renal method: Renal impairment categories as defined by the cited product label
Source date: DailyMed SPL version 9, posted Dec 16, 2024
Retrieved: 2026-11-07

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.7 Renal Impairment

Advanced renal disease is a reason to avoid diclofenac potassium powder for oral solution. If treatment is necessary, monitor renal function. Verify the formulation used for migraine.

RDM74-cambia-official-1 · Source locator: Renal guidance: 8.7 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d249ced1-4ca0-4f57-adcb-23440f58f659
Retrieved
2026-11-07
Renal-function method
Renal impairment categories as defined by the cited product label
Source date/version
DailyMed SPL version 9, posted Dec 16, 2024
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
d29e1e5a36367d58fd15fba52564a145b537549d20038d25a065b10772c01ad8

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-cambia&s1=RDM74-cambia-official&h1=1b3b14100661d0115405687b156c2aa3befcd38de22d3f9f9d3e027bf0de0f69

Top